LNA MODIFIED PHOSPHOROTHIOLATED OLIGONUCLEOTIDES
    1.
    发明申请
    LNA MODIFIED PHOSPHOROTHIOLATED OLIGONUCLEOTIDES 审中-公开
    LNA改性磷酸酯化寡核苷酸

    公开(公告)号:US20090176977A1

    公开(公告)日:2009-07-09

    申请号:US12162142

    申请日:2007-01-29

    IPC分类号: C07H21/02

    CPC分类号: C07H19/16 C07H19/06

    摘要: The current invention provides oligonucleotides which comprise a dinucleotide consisting of a 5′ locked nucleic acid (LNA), a phosphorothioate internucleoside linkage bond to a 3′ RNA or RNA analogue. The dinucleotide reduces the strength of hybridization of the oligonucleotide to a complementary nucleic acid target. The modification can be used to modulate hybridisation properties in both single stranded oligonucleotides and in double stranded siRNA complexes, particularly in oligonucleotides where the use of LNA results in excessively strong hybridisation properties.

    摘要翻译: 本发明提供了包含由5'锁定核酸(LNA),与3'RNA或RNA类似物的硫代磷酸核苷间键合键的二核苷酸的寡核苷酸。 二核苷酸降低寡核苷酸与互补核酸靶的杂交强度。 该修饰可用于调节单链寡核苷酸和双链siRNA复合物中的杂交性质,特别是在使用LNA导致过强的杂交性质的寡核苷酸中。

    Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
    9.
    发明申请
    Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease 审中-公开
    用于TNF超家族受体的接头开关寡聚体及其在治疗疾病中的应用

    公开(公告)号:US20090264353A1

    公开(公告)日:2009-10-22

    申请号:US11875277

    申请日:2007-10-19

    摘要: The present invention relates to compositions and methods for preparing splice variants of TNFalpha receptor (TNFR) in vivo or in vitro, and the resulting TNFR protein variants. Such variants may be prepared by controlling the splicing of pre-mRNA molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 or 8 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 or 8 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has therapeutic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.

    摘要翻译: 本发明涉及用于在体内或体外制备TNFα受体(TNFR)的剪接变体的组合物和方法,以及所得的TNFR蛋白质变体。 可以通过控制前mRNA分子的剪接和用剪接切换寡核苷酸或剪接切换寡聚体(SSO)调节蛋白质表达来制备这些变体。 根据本发明的优选SSO靶向TNFR1(TNFRSF1A)或TNFR2(TNFRSF1A)前mRNA的外显子7或8,通常导致在部分或全部外显子7或8中包含缺失的TNFR变体的产生。 发现针对外显子7的SSOs产生可溶形式的TNFR,其具有治疗炎性疾病的治疗益处。 SSO的特点是它们基本上无能力或不能招募RNaseH。